Video Player is loading.
10 seconds
Playback speed
Optimizing Therapy for ER+ Metastatic Breast Cancer: CDK 4/6 + Endocrine Therapy as 1st Line, Everolimus-Exemestane PI3K as a Reasonable Options for Mutant Patients
Comments 0
Login to view comments.
Click here to Login
